Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition

D. E. Vaughan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Experimental and clinical studies with angiotensin-converting enzyme (ACE) inhibitors have suggested that these agents may reduce the risk of atherothrombotic events. Recent studies have identified the role of angiotensin II and ACE in the regulation of fibrinolysis. There is now substantial evidence that the renin-angiotensin system (RAS) plays an important role in the regulation of vascular fibrinolytic balance. This recently recognized relationship may contribute to the vasculoprotective effects of ACE inhibitors.

Original languageEnglish (US)
JournalClinical Cardiology
Issue number12 SUPPL.
StatePublished - Dec 1 1997


  • Angiotensin-converting enzyme
  • Fibrinolysis
  • Plasminogen activator inhibitor type 1
  • Tissue-type plasminogen activator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition'. Together they form a unique fingerprint.

Cite this